变应原免疫治疗对变应性鼻炎的作用机制研究进展

孔勇刚; 焦沃尔; 陶泽璋; 陈始明

doi:10.13201/j.issn.2096-7993.2021.12.021

变应原免疫治疗对变应性鼻炎的作用机制研究进展

- 1.
  武汉大学人民医院耳鼻咽喉头颈外科(武汉，430060)
- 2.
  武汉大学人民医院耳鼻咽喉头颈外科研究所
基金项目:
国家自然科学基金项目(No：81770981)

详细信息

通讯作者: 陈始明，E-mail：shimingchen0468@163.com

^△ 审校者

中图分类号: R765.21

收稿日期: 2021-01-25

刊出日期: 2021-12-05

The research progress of mechanism of allergen immunotherapy in allergic rhinitis

More Information

Corresponding author: CHEN Shiming, E-mail: shimingchen0468@163.com

Received Date: 25 January 2021

Publish Date: 05 December 2021

摘要

- 鼻炎，变应性 /
- 变应原免疫治疗 /
- 免疫反应 /
- 作用机制
Abstract: Allergic rhinitis(AR) is a chronic non-infectious nasal mucosal disease mediated by IgE. It can be divided into seasonal and perennial according to the types of allergens.At present, there are many treatments for AR, among which allergen immunotherapy(AIT) is the only treatment option that can change the natural process of AR.AIT can improve innate immune response by reducing local hypertrophy, eosinophils, basophils and type 2 innate lymphocytes, and affect various T cells, B cells and many cytokines to regulate adaptive immunity. The mechanism of AIT on immune response is complex.In this review, the mechanism of immunotherapy on the innate and adaptive immunity of AR patients is highlighted, hoping to further understand the immunotherapy pathway of AR, and provide more theoretical basis for immunotherapy of AR.
- rhinitis, allergic /
- allergen immunotherapy /
- immune response /
- mechanism

HTML全文

参考文献(29)

[1]	Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis-executive summary[J]. Int Forum Allergy Rhinol, 2018, 8(2): 85-107. doi: 10.1002/alr.22070
[2]	Pfaar O, Nell MJ, Boot JD, et al. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients[J]. Allergy, 2016, 71(7): 967-976. doi: 10.1111/all.12860
[3]	Yuan X, Wang J, Li Y, et al. Allergy immunotherapy restores airway epithelial barrier dysfunction through suppressing IL-25-induced endoplasmic reticulum stress in asthma[J]. Sci Rep, 2018, 8(1): 7950. doi: 10.1038/s41598-018-26221-x
[4]	Hanif T, Dhaygude K, Kankainen M, et al. Birch pollen allergen immunotherapy reprograms nasal epithelial transcriptome and recovers microbial diversity[J]. J Allergy Clin Immunol, 2019, 143(6): 2293-2296.e11. doi: 10.1016/j.jaci.2019.02.002
[5]	Gueguen C, Bouley J, Moussu H, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy[J]. J Allergy Clin Immunol, 2016, 137(2): 545-558. doi: 10.1016/j.jaci.2015.09.015
[6]	Frischmeyer-Guerrerio PA, Keet CA, Guerrerio AL, et al. Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy[J]. Clin Immunol, 2014, 155(1): 47-59. doi: 10.1016/j.clim.2014.08.006
[7]	Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance[J]. J Allergy Clin Immunol, 2017, 140(5): 1250-1267. doi: 10.1016/j.jaci.2017.08.025
[8]	Schmid JM, Würtzen PA, Siddhuraj P, et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients[J]. Allergy, 2021, 76(5): 1528-1538. doi: 10.1111/all.14264
[9]	Caruso M, Cibella F, Emma R, et al. Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis[J]. Int Immunopharmacol, 2018, 60: 50-58. doi: 10.1016/j.intimp.2018.04.034
[10]	Kaminuma O, Kitamura N, Gotoh M, et al. Thrombospondin 1-mediated suppression of mast cell degranulation is involved in the efficacy of sublingual immunotherapy[J]. Allergol Int, 2019, 68S: S9-S10.
[11]	Shamji MH, Layhadi JA, Scadding GW, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response[J]. J Allergy Clin Immunol, 2015, 135(4): 913-921.e9. doi: 10.1016/j.jaci.2014.09.049
[12]	Hesse L, van Ieperen N, Habraken C, et al. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model[J]. Allergy, 2018, 73(4): 862-874. doi: 10.1111/all.13382
[13]	Mitthamsiri W, Pradubpongsa P, Sangasapaviliya A, et al. Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy[J]. Allergy Asthma Immunol Res, 2018, 10(6): 662-674. doi: 10.4168/aair.2018.10.6.662
[14]	van Rijt LS, Logiantara A, Canbaz D, et al. Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice[J]. Clin Exp Allergy, 2018, 48(11): 1402-1411. doi: 10.1111/cea.13254
[15]	Lou H, Huang Y, Ouyang Y, et al. Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial[J]. Allergy, 2020, 75(8): 2026-2036. doi: 10.1111/all.14218
[16]	Wen Y, Zhou L, Li Y, et al. Role of leptin in allergic rhinitis during sublingual immunotherapy[J]. Eur Arch Otorhinolaryngol, 2018, 275(11): 2733-2738. doi: 10.1007/s00405-018-5123-0
[17]	Meng Q, Liu X, Li P, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40 L signaling pathway in patients with allergic rhinitis[J]. Int Forum Allergy Rhinol, 2016, 6(8): 862-870. doi: 10.1002/alr.21743
[18]	Ihara F, Sakurai D, Yonekura S, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy[J]. Allergy, 2018, 73(9): 1823-1832. doi: 10.1111/all.13436
[19]	Huoman J, Papapavlou G, Pap A, et al. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children[J]. Pediatr Allergy Immunol, 2019, 30(5): 522-530.
[20]	Mattson L, Lentini A, Gawel DR, et al. Potential Involvement of Type I Interferon Signaling in Immunotherapy in Seasonal Allergic Rhinitis[J]. J Immunol Res, 2016, 2016: 5153184.
[21]	Gotoh M, Kaminuma O, Nakaya A, et al. Identification of biomarker sets for predicting the efficacy of sublingual immunotherapy against pollen-induced allergic rhinitis[J]. Int Immunol, 2017, 29(6): 291-300. doi: 10.1093/intimm/dxx034
[22]	Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy[J]. Allergy, 2019, 74(5): 976-985. doi: 10.1111/all.13684
[23]	Gonzalez M, Doña I, Palomares F, et al. Dermatophagoides pteronyssinus immunotherapy changes the T-regulatory cell activity[J]. Sci Rep, 2017, 7(1): 11949. doi: 10.1038/s41598-017-12261-2
[24]	Shamji MH, Layhadi JA, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy[J]. J Allergy Clin Immunol, 2019, 143(3): 1131-1142.e4. doi: 10.1016/j.jaci.2018.06.041
[25]	Yao Y, Wang N, Chen CL, et al. CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis[J]. Allergy, 2020, 75(10): 2599-2612. doi: 10.1111/all.14288
[26]	Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy[J]. Allergy, 2020, 75(5): 1121-1132. doi: 10.1111/all.14073
[27]	Shamji MH, Kappen J, Abubakar-Waziri H, et al. Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy[J]. J Allergy Clin Immunol, 2019, 143(3): 1067-1076. doi: 10.1016/j.jaci.2018.09.039
[28]	Kim JY, Han DH, Won TB, et al. Immunologic modification in mono-and poly-sensitized patients after sublingual immunotherapy[J]. Laryngoscope, 2019, 129(5): E170-E177. doi: 10.1002/lary.27721
[29]	黄秋菊, 魏欣, 林霞, 等. 粉尘螨舌下免疫治疗对海南地区变应性鼻炎患者特异性IgG4表达水平的影响[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(2): 135-139. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH202002009.htm